Cisplatin Plus Cetuximab With/Without Paclitaxel: Effective Alternative First-Line Regimens for Recurrent/Metastatic Head & Neck Cancer

chemotherapy, IV, chemo

Standard first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) is the EXTREME regimen of cetuximab, platinum chemotherapy (cisplatin or carboplatin), and 5-FU. While this regimen improves overall survival (OS) compared to chemotherapy alone (10.1 months vs 7.4 months, HR 0.80, P = .04), it is highly toxic and use[…]

Read More

Clinically Meaningful Benefit of Adding Nintedanib to Front-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma

metastatic pleural mesothelioma

Malignant pleural mesothelioma (MPM) is an aggressive cancer that is typically diagnosed at advanced stages, where prognosis is poor and survival short. Until recently, chemotherapy combination of cisplatin and pemetrexed has been standard of care. However, in the phase III MAPS trial, the addition of the angiogenesis inhibitor bevacizumab to standard chemotherapy demonstrated significant overall[…]

Read More

EMA Recommends Approval of Four New Anticancer Agents in September


On 14 September 2017, the European Medicines Agency (EMA) issued positive opinions for the approval of four new treatment options for oncology and hematology, including a biosimilar of trastuzumab for breast cancer, padeliporfin for vascular-targeted photodynamic therapy (VTP) of low-risk prostate cancer, maintenance niraparib for platinum-sensitive relapsed ovarian cancer, and nilotinib for pediatric patients. Green[…]

Read More

Rucaparib Affirms Role of PARP Inhibitor Maintenance in Relapsed Platinum-Sensitive Ovarian Cancer

Ovarian Cancer

Most patients with advanced ovarian cancer relapse after initial platinum-based therapy. The standard of care for patients with platinum-sensitive relapse is platinum-based therapy, followed by maintenance with targeted therapy in responding patients. Poly(ADP-ribose) polymerase (PARP) inhibitors are considered as the most active targeted therapies in ovarian cancer. While their greatest activity was demonstrated in patients[…]

Read More

Dabrafenib/Trametinib Combination and Nivolumab New Adjuvant Treatment Options for Stage III Melanoma


The current adjuvant treatment options for high-risk patients with resectable melanoma include interferon and the cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor ipilimumab. Compared to placebo, ipilimumab (10 mg/kg) prolonged relapse free survival (RFS) and showed significant 5-year survival benefit in high-risk patients with melanoma, but at the cost of serious toxicity. In the metastatic[…]

Read More

FDA Approves Seven New Anticancer Treatments in September

FDA approvals for NSCLC and lymphoma

In September, the US Food and Drug Administration (FDA) approved seven new indications in oncology and hematology, including the first ever biosimilar monoclonal antibody (mAb) for the treatment of cancer. Bevacizumab Biosimilar Now Available in the United States. On 14 September, the FDA granted approval to bevacizumab-awwb (Mvasi™, Amgen Inc), a biosimilar of Avastin®. This[…]

Read More

Combo Nivolumab and Ipilimumab: A New First-Line Standard for Advanced RCC

Micrograph of Renal Cell Carcinoma (RCC)

Currently, first-line treatment of advanced renal cell carcinoma (RCC) is most often a vascular endothelial growth factor receptor (VEGFR)–targeting tyrosine kinase inhibitor (TKI), such as sunitinib. In patients who progress on first-line treatment with TKI, immunotherapy with the programmed death receptor 1 (PD-1)–targeting antibody, nivolumab, is standard. In the phase Ib CheckMate 016 study, nivolumab[…]

Read More

Addition of Abemaciclib to First-Line Therapy Improves Outcomes in Advanced HR-Positive Breast Cancer

26 Sept 2017_GettyImages-614138202_microphone and crowd_892X469

Inhibitors of cyclin-dependent kinase 4/6 (CDK4/6) have become an important part of the treatment plan for patients with advanced, hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. One such agent, abemaciclib, recently demonstrated significantly improved efficacy in combination with fulvestrant (compared with placebo), and a tolerable safety profile, in the phase[…]

Read More

Is Osimertinib the New First-Line Standard of Care for All EGFR-Mutant Non-Small Cell Lung Cancer?


First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are current standard first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC). Despite initial response to these agents, the majority of patients develop acquired resistance within approximately one year of treatment initiation. In more than 50% of patients, the mechanism of acquired resistance[…]

Read More

Practice-Changing Results With Durvalumab After Chemoradiation in Locally Advanced NSCLC

Immunotherapy, NSCLC, lung cancer, durvalumab, Consolidation therapy

Recent data from trials of programmed death receptor-1 (PD-1) and PD-L1 inhibitors have changed the standard of care for patients with metastatic non-small cell lung cancer (NSCLC) in both the first-line and second-line settings. The standard of care therapy for patients with stage III, locally advanced, unresectable NSCLC is platinum-based doublet chemotherapy, concurrent with radiotherapy[…]

Read More